Wang, L., Liu, C., Ning, F., Liu, H., Cui, J., Su, W., Song, X., Wang, Y. Y., Li, Q., Changhua, Y., Cheng, X., Dang, X., Hao, F., Wei, T., Wei, Y., Wang, H., Wang, J., Qiu, X., Kang, X., Yu, J. (2026). A double-blind, double-dummy, randomized, controlled phase 3 trial of iparomlimab and tuvonralimab (QL1706) vs QL1604 as consolidation therapy following concurrent or sequential chemoradiotherapy (cCRT/sCRT) in patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8133